VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 9, 2014) - Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) ("Calyx" or the "Company") announces that it has entered into an agreement with BDC Capital Inc. and Agrisoma Biosciences Inc. ("Agrisoma") pursuant to which Calyx has agreed to waive its pre-emptive right in order to allow a third party to finance Agrisoma. The proposed Agrisoma financing, if it were to proceed as proposed and without Calyx's participation will, upon closing, dilute Calyx's interest in Agrisoma from 49.96% to approximately 29%. Following an evaluation by an Independent Committee of Calyx's board of directors, it was determined that in Calyx's view, Agrisoma's business had not progressed as expected, and no options for financing Agrisoma could be found that would be satisfactory to shareholders of Calyx.
Additionally, intellectual property ("IP") which was exclusively licensed to Agrisoma by Calyx is no longer under exclusive license to Agrisoma. With the IP reverting to Calyx, Calyx is now able to license and utilize its IP in other agricultural sector opportunities that it is currently investigating. The unique and powerful features of this technology provide clear advantages for the development of plant-based products. Calyx is in discussions and pursuing a number of new business opportunities in the agriculture and agri-pharmaceutical sectors including the MMPR (Marijuana for Medical Purposes Regulations) and marijuana biotech where we can bring our depth of agriculture capacities.
Accordingly, the Calyx board has determined to cancel the dilutive non-brokered private placement for the issuance of up to 35 million units at a price of six cents per unit for cash proceeds of up to $2.1-million previously announced on March 31, 2014.
Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agricultural technology company which is developing early stage agriculture ventures. Calyx brings its depth of experience, capital and other capacity, including its proprietary intellectual property, to enhance plant yields. In addition to Calyx's shareholding in Agrisoma Biosciences Inc., a company which is producing a non-food energy feedstock crop for bioenergy, Calyx is pursuing agri-pharmaceutical opportunities in the MMPR (Marijuana for Medical Purposes Regulations) and the agri-tech space. The medical marijuana industry is in its infancy and is an emerging multibillion-dollar opportunity undergoing significant regulatory and legal reform which offers strong growth opportunities to early participants. For further information about Calyx, please visit www.calyxbio.com.
Forward-Looking Statements: This document contains certain forward-looking statements concerning Calyx, as well as other expectations, plans, goals, objectives, information or statements about future events, conditions, or performance that may constitute "forward-looking statements" or "forward-looking information" under applicable securities legislation. Such statements or information involve substantial known and unknown risks and uncertainties, certain of which are beyond Calyx's control.
Such forward-looking statements or information are based on a number of assumptions, which may prove to be incorrect.
Although Calyx believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because Calyx can give no assurance that such expectations will prove to be correct. Forward-looking statements or information are based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by Calyx and described in the forward-looking statements or information.
The forward-looking statements or information contained in this news release are made as of the date hereof and Calyx undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise unless so required by applicable securities laws or the TSX Venture Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT: Calyx Bio-Ventures Inc. Don Konantz President & CEO 604-649-5961 email@example.com Calyx Bio-Ventures Inc. Investor Relations: Keir Reynolds 778-998-9242 firstname.lastname@example.org www.calyxbio.com Source: Calyx Bio-Ventures Inc.